The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.

When Wall Street analyst Ronny Gal joined Swiss pharma giant Novartis in the newly created role of chief strategy and growth officer, he came to the table with industry know-how and an outsider’s ...

French drugmaker Sanofi has been playing the long game when it comes to the blockbuster Dupixent, and the results are starting to show. First approved for atopic dermatitis in 2017, the skin and ...

Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its ...

The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large ...

Nimbus Therapeutics’ head of R&D dishes on what’s next in AI-enabled drug discovery, years after Takeda completed its ...

The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What ...

It’s been a record year so far for biotech bankruptcies. As of October, 28 biotech companies have gone bust compared to 20 last year and just nine in 2021. A number of factors have contributed to the ...

Basecamp Research just netted $140 million in a series C fundraising round that valued the company at $800 million, according ...

Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven ...